Mostrar el registro sencillo del ítem

Similar Kinetics of Pulmonary SARS-CoV-2 Load in Intensive Care Unit Patients with COVID-19 Pneumonia with or Without Autoantibodies Neutralizing Type I Interferons.

dc.rights.licenseopenen_US
dc.contributor.authorLE STANG, Valentine
dc.contributor.authorBASTARD, Paul
dc.contributor.authorLANGOUET, Elise
dc.contributor.authorPINETON DE CHAMBRUN, Marc
dc.contributor.authorCHOMMELOUX, Juliette
dc.contributor.authorGERVAIS, Adrian
dc.contributor.authorBIZIEN, Lucy
dc.contributor.authorPUEL, Anne
dc.contributor.authorCOBAT, Aurélie
dc.contributor.authorMAYAUX, Julien
dc.contributor.authorDEMOULE, Alexandre
dc.contributor.authorCASANOVA, Jean-Laurent
dc.contributor.authorBOUTOLLEAU, David
dc.contributor.authorCOMBES, Alain
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBURREL, Sonia
dc.contributor.authorLUYT, Charles-Edouard
dc.date.accessioned2025-01-07T14:19:47Z
dc.date.available2025-01-07T14:19:47Z
dc.date.issued2024-11-20
dc.identifier.issn1573-2592en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/204169
dc.description.abstractEnThe pathogenesis of life-threatening coronavirus disease 2019 (COVID-19) pneumonia in ICU patients can involve pre-existing auto-antibodies (auto-Abs) neutralizing type I interferons (IFNs). The impact of these auto-Abs on SARS-CoV-2 clearance in the lower respiratory tract (LRT) is unclear. We performed a retrospective study in 99 ICU patients with COVID-19 pneumonia between March and May 2020. LRT SARS-CoV-2 load (intensity and duration) was analyzed according to the presence or not of circulating auto-Abs neutralizing type I IFNs. Among the 99 included patients, 38 (38%) were positive for auto-Abs neutralizing type I IFNs, with 5 (5%) harboring auto-Abs neutralizing IFN-α2 at any concentration, while 33 (33%) had auto-Abs neutralizing only IFN-ω at the lower concentration. SARS-CoV-2 load in the LRT and duration of viral shedding, were similar in patients with or without auto-Abs neutralizing type I IFNs. Patients with auto-Abs had the same mortality than those without auto-Abs, despite greater occurrence of renal failure and ECMO support, and longer duration of mechanical ventilation and ICU stay. In summary, 5% of patients with critical COVID-19 pneumonia carried auto-Abs neutralizing IFN-α2, while about 1/3 harbored auto-Abs neutralizing low concentrations of IFN-ω. The detection of either type of auto-Abs did not impact LRT viral clearance and mortality, although it was associated with greater morbidity and a longer hospitalization. These findings suggest that similar albeit hitherto unknown mechanisms of disease drive critical COVID-19 pneumonia in patients without auto-Abs against type I IFNs.
dc.language.isoENen_US
dc.subject.enHumans
dc.subject.enCOVID-19
dc.subject.enMale
dc.subject.enSARS-CoV-2
dc.subject.enFemale
dc.subject.enInterferon Type I
dc.subject.enMiddle Aged
dc.subject.enAutoantibodies
dc.subject.enRetrospective Studies
dc.subject.enIntensive Care Units
dc.subject.enAntibodies
dc.subject.enNeutralizing
dc.subject.enAged
dc.subject.enViral Load
dc.subject.enAdult
dc.subject.enKinetics
dc.title.enSimilar Kinetics of Pulmonary SARS-CoV-2 Load in Intensive Care Unit Patients with COVID-19 Pneumonia with or Without Autoantibodies Neutralizing Type I Interferons.
dc.title.alternativeJ Clin Immunolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s10875-024-01839-xen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed39565497en_US
bordeaux.journalJournal of Clinical Immunologyen_US
bordeaux.page45en_US
bordeaux.volume45en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue1en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04871072
hal.version1
hal.date.transferred2025-01-07T14:19:49Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Clinical%20Immunology&rft.date=2024-11-20&rft.volume=45&rft.issue=1&rft.spage=45&rft.epage=45&rft.eissn=1573-2592&rft.issn=1573-2592&rft.au=LE%20STANG,%20Valentine&BASTARD,%20Paul&LANGOUET,%20Elise&PINETON%20DE%20CHAMBRUN,%20Marc&CHOMMELOUX,%20Juliette&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem